NSE:NATCOPHARM 1 December 2025 - 8 December 2025

Natco Pharma Limited is back in the spotlight as the stock trades lower on 8 December 2025 even while the company closes a landmark acquisition in South Africa and navigates life after its blockbuster Revlimid windfall.

Natco Pharma has had a busy few months: a big overseas acquisition in South Africa, a fresh USFDA inspection with Form 483 observations, strong-but-normalising earnings, and a credit-rating reaffirmation that reassured debt markets. The share price is finally stabilising after a brutal fall earlier in 2025, but the market is still arguing about what the stock is really worth.